{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:09:56Z","timestamp":1785784196714,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00109-020-02003-9","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:03:12Z","timestamp":1609786992000},"page":"663-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A cell-based drug delivery platform for treating central nervous system inflammation"],"prefix":"10.1007","volume":"99","author":[{"given":"Oren","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Rothhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Mascanfroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De Biasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Perrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Yeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Kenison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helia","family":"Safaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Musabeyezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Heinelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Siders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Multon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rothblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Massadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alaamery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-0736","authenticated-orcid":false,"given":"Francisco J.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2003_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA (2012) Multiple sclerosis. J Clin Invest 122:1180\u20131188","journal-title":"J Clin Invest"},{"key":"2003_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517","journal-title":"Lancet"},{"key":"2003_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1352458512439437","volume":"19","author":"E Rosti-Otaj\u00e4rvi","year":"2013","unstructured":"Rosti-Otaj\u00e4rvi E, H\u00e4m\u00e4l\u00e4inen P (2013) Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis. Mult Scler J 19:31\u201345","journal-title":"Mult Scler J"},{"key":"2003_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/1352458509358088","volume":"16","author":"C Ford","year":"2010","unstructured":"Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R et al (2010) Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler (Houndmills, Basingstoke, England) 16:342\u2013350","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"key":"2003_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitham RH, The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285\u2013294","journal-title":"Ann Neurol"},{"key":"2003_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098\u20131107","journal-title":"N Engl J Med"},{"key":"2003_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"2003_CR8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.intimp.2010.06.019","volume":"10","author":"MJ Hoogduijn","year":"2010","unstructured":"Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, Dahlke MH (2010) The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 10:1496\u20131500","journal-title":"Int Immunopharmacol"},{"key":"2003_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pathol-011110-130230","volume":"6","author":"NG Singer","year":"2011","unstructured":"Singer NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech 6:457\u2013478","journal-title":"Annu Rev Pathol Mech"},{"key":"2003_CR10","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2002-07-2104","volume":"101","author":"M Krampera","year":"2003","unstructured":"Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 101:3722\u20133729","journal-title":"Blood."},{"key":"2003_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.TP.0000045055.63901.A9","volume":"75","author":"WT Tse","year":"2003","unstructured":"Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 75:389\u2013397","journal-title":"Transplantation."},{"key":"2003_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.coi.2010.10.012","volume":"22","author":"A Uccelli","year":"2010","unstructured":"Uccelli A, Prockop DJ (2010) Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 22:768\u2013774","journal-title":"Curr Opin Immunol"},{"key":"2003_CR13","first-page":"95","volume":"2","author":"JP Holloman","year":"2013","unstructured":"Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI (2013) The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cells 2:95\u2013107","journal-title":"Am J Stem Cells"},{"key":"2003_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jnr.20962","volume":"84","author":"J Zhang","year":"2006","unstructured":"Zhang J, Li Y, Lu M, Cui Y, Chen J, Noffsinger L, Elias SB, Chopp M (2006) Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res 84:587\u2013595","journal-title":"J Neurosci Res"},{"key":"2003_CR15","first-page":"69","volume":"6","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, Morando S, Bonanno S, Bonanni I, Leonardi A, Mancardi G (2011) Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? Stem Cell Res Ther 6:69\u201372","journal-title":"Stem Cell Res Ther"},{"key":"2003_CR16","doi-asserted-by":"crossref","unstructured":"Saeed S, Amir Ali S, Oger J (2014) The use of mesenchymal stem cells in the treatment of multiple sclerosis: an overview of open labels and ongoing studies. J Neurol Neurophysiol 5","DOI":"10.4172\/2155-9562-5-1000219"},{"key":"2003_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","volume":"67","author":"D Karussis","year":"2010","unstructured":"Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori J, Kassis I et al (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187\u20131194","journal-title":"Arch Neurol"},{"key":"2003_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.biomaterials.2016.03.023","volume":"91","author":"O Levy","year":"2016","unstructured":"Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM (2016) A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91:140\u2013150","journal-title":"Biomaterials."},{"key":"2003_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jconrel.2014.07.042","volume":"192","author":"L Pascucci","year":"2014","unstructured":"Pascucci L, Cocc\u00e8 V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Vigan\u00f2 L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A (2014) Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release 192:262\u2013270","journal-title":"J Control Release"},{"key":"2003_CR20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.celrep.2015.01.057","volume":"10","author":"O Levy","year":"2015","unstructured":"Levy O, Mortensen LJ, Boquet G, Tong Z, Perrault C, Benhamou B, Zhang J, Stratton T, Han E, Safaee H, Musabeyezu J, Yang Z, Multon MC, Rothblatt J, Deleuze JF, Lin CP, Karp JM (2015) A small-molecule screen for enhanced homing of systemically infused cells. Cell Rep 10:1261\u20131268","journal-title":"Cell Rep"},{"key":"2003_CR21","first-page":"389","volume":"17","author":"JS Nixon","year":"1991","unstructured":"Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, Kumar H, Lawton G, Lewis EJ, Mulqueen M (1991) Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity. Drugs Exp Clin Res 17:389\u2013393","journal-title":"Drugs Exp Clin Res"},{"key":"2003_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/ni1275","volume":"6","author":"A Luster","year":"2005","unstructured":"Luster A, Alon R, von Andrian U (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6:1182\u20131190","journal-title":"Nat Immunol"},{"key":"2003_CR23","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2174\/156802609789007372","volume":"9","author":"DH Boschelli","year":"2009","unstructured":"Boschelli DH (2009) Small molecule inhibitors of PKCTheta as potential antiinflammatory therapeutics. Curr Top Med Chem 9:640\u2013654","journal-title":"Curr Top Med Chem"},{"key":"2003_CR24","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.2174\/138161212802651625","volume":"18","author":"S Chand","year":"2012","unstructured":"Chand S, Mehta N, Bahia MS, Dixit A, Silakari O (2012) Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders. Curr Pharm Des 18:4725\u20134746","journal-title":"Curr Pharm Des"},{"key":"2003_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1042\/BST20140167","volume":"42","author":"A Curnock","year":"2014","unstructured":"Curnock A, Bolton C, Chiu P, Doyle E, Fraysse D, Hesse M, Jones J, Weber P, Jimenez JM (2014) Selective protein kinase C\u03b8 (PKC\u03b8) inhibitors for the treatment of autoimmune diseases. Biochem Soc Trans 42:1524\u20131528","journal-title":"Biochem Soc Trans"},{"key":"2003_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jneuroim.2013.01.003","volume":"256","author":"A Lieu","year":"2013","unstructured":"Lieu A, Tenorio G, Kerr BJ (2013) Protein kinase C gamma (PKC\u03b3) as a novel marker to assess the functional status of the corticospinal tract in experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 256:43\u201348","journal-title":"J Neuroimmunol"},{"key":"2003_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1021\/jm301465a","volume":"56","author":"J Jimenez","year":"2013","unstructured":"Jimenez J, Boyall D, Brenchley G, Collier P, Davis C, Fraysse D et al (2013) Design and optimization of selective protein kinase C \u03b8 (PKC\u03b8) inhibitors for the treatment of autoimmune diseases. J Med Chem 56:1799\u20131810","journal-title":"J Med Chem"},{"key":"2003_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature06880","volume":"453","author":"FJ Quintana","year":"2008","unstructured":"Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL (2008) Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature. 453:65\u201371","journal-title":"Nature."},{"key":"2003_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1750-3639.2000.tb00272.x","volume":"10","author":"I Tsunoda","year":"2000","unstructured":"Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS (2000) Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol 10:402\u2013418","journal-title":"Brain Pathol"},{"key":"2003_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0165-5728(92)90016-E","volume":"38","author":"BL McRae","year":"1992","unstructured":"McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD (1992) Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38:229\u2013240","journal-title":"J Neuroimmunol"},{"key":"2003_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.immuni.2012.05.023","volume":"37","author":"SC Starossom","year":"2012","unstructured":"Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D, Wang Y, Elyaman W, Khoury SJ, Rabinovich GA (2012) Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 37:249\u2013263","journal-title":"Immunity."},{"key":"2003_CR32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/glia.20841","volume":"57","author":"L Bai","year":"2009","unstructured":"Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 57:1192\u20131203","journal-title":"Glia."},{"key":"2003_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1084\/jem.20021603","volume":"197","author":"E Bettelli","year":"2003","unstructured":"Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197:1073\u20131081","journal-title":"J Exp Med"},{"key":"2003_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jns.2012.12.009","volume":"333","author":"JA Cohen","year":"2013","unstructured":"Cohen JA (2013) Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci 333:43\u201349","journal-title":"J Neurol Sci"},{"key":"2003_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ana.24009","volume":"74","author":"SL Hauser","year":"2013","unstructured":"Hauser SL, Chan JR, Oksenberg JR (2013) Multiple sclerosis: prospects and promise. Ann Neurol 74:317\u2013327","journal-title":"Ann Neurol"},{"key":"2003_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.stem.2012.02.005","volume":"10","author":"SH Ranganath","year":"2012","unstructured":"Ranganath SH, Levy O, Inamdar MS, Karp JM (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10:244\u2013258","journal-title":"Cell Stem Cell"},{"key":"2003_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2007.11.005","volume":"134","author":"K Nagahama","year":"2008","unstructured":"Nagahama K, Ogawa A, Shirane K, Shimomura Y, Sugimoto K, Mizoguchi A (2008) Protein kinase C \u03b8 plays a fundamental role in different types of chronic colitis. Gastroenterology. 134:459\u2013469","journal-title":"Gastroenterology."},{"key":"2003_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/4723","volume":"5","author":"T Zhou","year":"1999","unstructured":"Zhou T, Song L, Yang P, Wang Z, Lui D, Jope RS (1999) Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat Med 5:42\u201348","journal-title":"Nat Med"},{"key":"2003_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0898-6568(96)00097-6","volume":"9","author":"JE Merritt","year":"1997","unstructured":"Merritt JE, Sullivan JA, Tse J, Wilkinson S, Nixon JS (1997) Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction. Cell Signal 9:53\u201357","journal-title":"Cell Signal"},{"issue":"Pt 2","key":"2003_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1042\/bj2940335","volume":"294","author":"SE Wilkinson","year":"1993","unstructured":"Wilkinson SE, Parker PJ, Nixon JS (1993) Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 294(Pt 2):335\u2013337","journal-title":"Biochem J"},{"key":"2003_CR41","doi-asserted-by":"publisher","first-page":"e28321","DOI":"10.1371\/journal.pone.0028321","volume":"6","author":"A Pessina","year":"2011","unstructured":"Pessina A, Bonomi A, Cocc\u00e8 V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Vigan\u00f2 L, Locatelli A, Ciusani E, Cappelletti G, Cartelli D, Arnaldo C, Parati E, Marfia G, Pallini R, Falchetti ML, Alessandri G (2011) Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One 6:e28321","journal-title":"PLoS One"},{"key":"2003_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jconrel.2013.12.019","volume":"176","author":"H He","year":"2014","unstructured":"He H, Ye J, Wang Y, Liu Q, Chung HS, Kwon YM, Shin MC, Lee K, Yang VC (2014) Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release 176:123\u2013132","journal-title":"J Control Release"},{"key":"2003_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s11671-017-1980-5","volume":"12","author":"X Dong","year":"2017","unstructured":"Dong X, Niu Y, Ding Y, Wang Y, Zhao J, Leng W, Qin L (2017) Formulation and drug loading features of nano-erythrocytes. Nanoscale Res Lett 12:202","journal-title":"Nanoscale Res Lett"},{"key":"2003_CR44","doi-asserted-by":"crossref","unstructured":"Ankrum JA, Dastidar RG, Ong JF, Levy O, Karp JM (2014) Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci Rep 4","DOI":"10.1038\/srep04645"},{"key":"2003_CR45","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.stemcr.2016.05.003","volume":"6","author":"SH Ranganath","year":"2016","unstructured":"Ranganath SH, Tong Z, Levy O, Martyn K, Karp JM, Inamdar MS (2016) Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineering. Stem Cell Rep 6:926\u2013939","journal-title":"Stem Cell Rep"},{"key":"2003_CR46","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1021\/nl301658q","volume":"12","author":"C Xu","year":"2012","unstructured":"Xu C, Miranda-Nieves D, Ankrum JA, Matthiesen ME, Phillips JA, Roes I, Wojtkiewicz GR, Juneja V, Kultima JR, Zhao W, Vemula PK, Lin CP, Nahrendorf M, Karp JM (2012) Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly(lactide-co-glycolide) microparticles. Nano Lett 12:4131\u20134139","journal-title":"Nano Lett"},{"key":"2003_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/imm.12046","volume":"138","author":"F Quintana","year":"2013","unstructured":"Quintana F (2013) The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology. 138:183\u2013189","journal-title":"Immunology."},{"key":"2003_CR48","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.4106","volume":"22","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao CC, Patel B, Yan R, Blain M, Alvarez JI, K\u00e9bir H, Anandasabapathy N, Izquierdo G, Jung S, Obholzer N, Pochet N, Clish CB, Prinz M, Prat A, Antel J, Quintana FJ (2016) Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22:586\u2013597","journal-title":"Nat Med"},{"key":"2003_CR49","doi-asserted-by":"publisher","first-page":"e9478","DOI":"10.1371\/journal.pone.0009478","volume":"5","author":"FJ Quintana","year":"2010","unstructured":"Quintana FJ, Iglesias AH, Farez MF, Caccamo M, Burns EJ, Kassam N, Oukka M, Weiner HL (2010) Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish. PLoS One 5:e9478","journal-title":"PLoS One"},{"key":"2003_CR50","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1172\/JCI200417772","volume":"113","author":"A Mimran","year":"2004","unstructured":"Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR (2004) DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J Clin Invest 113:924\u2013932","journal-title":"J Clin Invest"},{"key":"2003_CR51","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cell.2015.08.025","volume":"162","author":"F Farez Mauricio","year":"2015","unstructured":"Farez Mauricio F, Mascanfroni Ivan D, M\u00e9ndez-Huergo Santiago P, Yeste A, Murugaiyan G, Garo Lucien P et al (2015) Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell. 162:1338\u20131352","journal-title":"Cell."},{"key":"2003_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.3868","volume":"21","author":"ID Mascanfroni","year":"2015","unstructured":"Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM, Pan F, Priel A, Clish CB, Robson SC, Quintana FJ (2015) Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-[alpha]. Nat Med 21:638\u2013646","journal-title":"Nat Med"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-02003-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T13:50:48Z","timestamp":1674827448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-02003-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-02003-9","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted and ethical approval was obtained from the Institutional Animal Care and Use Committee at Harvard Medical School.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Q. W., T. M., C.P., W. S., M.-C. M., and J.R. are employed by Sanofi. JMK has been a paid consultant and or equity holder for companies including Stempeutics, Sanofi, Celltex, LifeVaultBio, Tissium, Takeda, Skintifique, Alivio Therapeutics, Altrix Bio, Ligandal, Vyome, Camden Partners, Stemgent, Gyro Gear, Mirakel, Landsdowne Labs, Biogen, Pancryos, Element Biosciences, Frequency Therapeutics, Molecular Infusions, Quthero, and Mesoblast. JMK is also an inventor on a patent that was licensed to Mesoblast. JMK holds equity in Frequency Therapeutics, a company that has licensed IP generated by JMK that may benefit financially if the IP is further validated. The interests of JMK were reviewed and are subject to a management plan overseen by his institutions in accordance with its conflict of interest policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}